Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Revenio Financial Statement Bulletin 2025

By Inderes2/11/2026, 1:00 PM
Revenio Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Jouni Toijala
00:01 - 09:39

Good afternoon from snowy Finland and welcome to Revenio. Q4 and full year 2025 Earnings Call. My name is Jouni Toijala. I'm the Group CEO for Revenio. And then with me, as always, we have Robin Pulkkinen here as CFO. Plan for today is to go through the business highlights for Q4 2025. And then a couple of highlights also from the whole 2025. And then we will recap the three-year strategy period, focusing on the strategy execution during 2025. And then Robin is going to take over and go through the financials for Q4 2025 and then the whole year 2025. And then we'll finish up with the guidance for 2026. And of course, the Q&A at the end, Q4 net sales grew to 31.2 million, with reported growth of 2.2% and currency-adjusted growth of 8.6%. And if you look back at Q4 from a regional perspective. So, Q4 US sales grew strongly, and we achieved an all-time sales record in the USA during December. There was also strong growth in the Europe, Middle East, Africa (EMEA) region. And if you look for the APAC. So a bit more similar trend during Q4 for APAC as we had for Q3. So the sales were down year on year. But on the positive note, now the tide turned and APAC started to perform a bit better during the Q4 compared to Q3. On the profit side, quite a lot down. I think it's good to understand a couple of things regarding the EBIT development and in comparison to last year. So we had a couple of bigger buckets here, which had an impact on the EBIT performance for Q4. So the first one was related to the delayed price increases that cost the bottom line about half a million euros, 2% on the gross margin level. And then we had roughly half a million non-recurring costs and then a bit more increased costs on the FDA side. And then if you go back to the 2024 for Q4. So we had roughly a currency tailwind of about €860,000, which then also passed through to the bottom line. But Robin is going to cover this one in more detail. But I think these things are good to keep in mind. Cash flow extremely strong. So, cash flow was just under 16 million compared to 10 million in the comparable quarter. More or less in the middle of the guidance. So, currency-adjusted net sales growth was 9.1%, totaling €109.7 million, with profitability at a good level. And then, perhaps a highlight from 2025 linked also to the cash flow. So strong cash flow, ending up to roughly 30 million from the 23 million. And perhaps this is the right time to say a big thanks for all our customers. So they have been trusting us during 2025, and then of course, for all our partners and especially for the team. I think the year 2025 was a good year for us in this turbulent market environment. Then, doing a recap of the strategy and main drivers which have been driving our growth for quite many years. And we don't see that changing at all. Even though we have had turbulence in the geopolitical environment, also on the economic side. So the megatrends have been and they are going to support our growth also in the long run. People are aging. There are more lifestyle-related diseases. So really, the need for care is growing globally as we are going to have more and more patients every day. And then if we compare to the amount of the available resources. So the gap is going to be widening. And what we have observed, especially during 2025, is a pick-up in our retina screening solution in general. So these trends have been driving our growth, and they are going to be there for sure for years to come. When we entered the strategy period, we laid out four cornerstones. So the first one related to devices, which is to improve the quality of clinical diagnostics with targeted product innovations. Then we had the solution side as the second, then sales and operations, and then the people part. During 2025, we have been able to get new products out in the market. First example is the MAIA microperimeter. Then also on the solution side, the data management solution FDA cleared in the USA was launched during 2025 and now in first client installations. Then, on the solution side, we have been really successful on rolling out the screening solution. It has already been driving our hardware sales during 2025, especially in new segments where we haven't been before. And a good example, I think, is the first numbers that we are providing. So, even in this short period, we now have over 350 live sites up and running, and at this stage, that number is even higher; additionally, the report volumes are also increasing. So we have been doubling them during 2025. On the sales side, it was a strong year for sales. So all product categories grew during 2025 in all regions, even in the APAC, if we take into account the strong Q1 which we had in APAC, and then of course, ending up with an all-time sales record in December in the USA. From the operations side, we were really well prepared to take the stock levels up because of the tariffs. So, full on the money on that one. And then we have been able to increase product quality across all product categories. On the people side, we have been putting a lot of effort into leadership team development and leadership development in general. And then also we laid out the new Product Operating Model during the second half 2025, and I think these all have been contributing our ability to maintain profitable growth during 2025. So, looking at the priorities for the remaining part of 2026. So top three items here are, of course, to focus on the sales and marketing side. So we are going to put even more focus on that one in order to guarantee the sales growth. Also during 2026, we have been constantly investing in R&D. So in our mind, we have a really compelling product portfolio. Also in the future, on the Tonometry, fundus imaging, Perimetry, and software solution sides. So the key is to focus on those areas and get new products out on time. And of course, the topic that we have been discussing in quite many earnings calls, and there have always been quite many questions around M&A. So that's going to be high on our agenda also in the coming quarters. But I think Robin, before giving the floor to you. So we are starting a new strategy period. Early 2027. So, we are planning to have a Capital Markets Day during the fall 2026. Keep an eye on the more detailed dates. So we'll come back to this one. Over to you Robin.

Robin Pulkkinen
09:40 - 18:54

Thank you Jouni. So let me run through the numbers a bit. So, you already covered the sales: 8.6% growth in the last quarter, FX adjusted, and 9.1% for the whole year. Basically, the sales didn't include any of those larger deals we were discussing at the end of Q3. None of those are gone or have been lost. So they're all still in the works. And looking quite promising going into this year for the company. And from the sales point of view, the margin has been a surprise. For the market, clearly, the price increases were not fully implemented in the US during the last quarter. You can see it clearly visible here. So we ran out of the tariff-free inventory at the end of Q3. And the impact is evident here, as the price increases were not yet reflected, which really had an impact on the gross margin. Like we discussed earlier, though, we are raising the prices to cover for the cost of the tariff. But basically, for example, if you had a thousand in cost of goods sold as tariff and you had 1000 of revenue, it will have a lowering impact on the percentage. But the cost in euros should be covered by the increases. So if you have the tariffs running through, it will have a lowering impact on the gross margin. But it shouldn't be this low. So we're working on getting all those fixed early this year. And looking at the ASP reports, we're seeing signals or signs that prices are going up in the US, and this will hopefully be fixed in the coming months. Basically, I don't think the price increases will maybe get us closer to 70. But that's probably a more realistic level for the coming quarters. As long as the tariffs are at the level where they are today. I'll get back to the profitability a bit more later. Basically, our earnings per share is slightly down for the year from last year. Net gearing was -13.3%. So, our balance sheet is in a very healthy situation. So I also have more slides on those to come. Regarding sales, some people have been wondering why the FX impact was so big, and Jouni also mentioned that slightly earlier. But for the comparison period, some of you hopefully remember that at the end of Q2 2024, we made some adjustments to the balance sheet where we reallocated and restructured some of the foreign currency balances into different parts of the balance sheet to avoid a direct impact or revaluation hit to our top line. Last Q4 24 was the last quarter. We still had those, and in that quarter, there was €860,000 of FX adjustment to the top line from the balance sheet items, which basically flows through the whole P&L. So, when those are removed, we exclude them from the top line for reporting currency-adjusted growth. But actually, the same 860 also flows through to the EBIT line. So, no larger deals were mentioned. So it's really business as usual for the quarter. We left the guidance gap quite wide still at the end of Q3, with the assumption of the possibility to close some of those. But they didn't materialize yet. But we're still working on them, and I'm quite positive how things are looking. So, the profitability. I explained the FX part. So, looking at why the revenue profitability is down from Q4 2024. The FX had an 860 thousand impact. Then we had clinical trial costs, which are half a million higher, related to the FDA trials. The screening platform FDA trials are expected to continue into this year. We're still now in the pre-study phase based on the findings. Then we'll have a better understanding of how the actual clinical trial is going to be done and what scope. The total cost is not yet fully clear at this point. But we're talking about above a million, definitely more, most likely around 1.5 million cost for this year. And those are hitting the PNL. So there is something we don't capitalize. So the price increase delays also had an impact on the profit. And then finally, we had the non-recurring costs during the quarter. Basically related to negotiations and other one-off projects, and transitioning into 2026, we have always been seen as a scalable company. If you leave out the FDA clinical trial costs, whose one-off nature is, in some ways, an assumption or expectation. Expectation is that we are going to target to grow the top line faster than the other operating expenses. So getting scale back to the bottom line. The balance sheet remains strong. There hasn't been any major shift here for the last couple of years. We had over 26 million in the bank at the end of the year, versus a little bit more than 20 million a year earlier. The interest bearing debt was roughly 11 million at the end of the year. And the same picture you can see here. Net gearing is coming down fast, driven by strong cash generation. The interest-bearing debt breaks down. So, basically, we have 5.8 million left of the bank loan. We withdrew for acquiring Centervue. So basically six quarters. So the quarterly installment is roughly 1 million and a quarter. So next six quarters will be bank debt free at least. And then the remaining part is the right-of-use liabilities, which are about 5 million at the end of the year. Cash flow, very strong record high, almost 16 million within Q4, basically driven by efficient working capital management and then lower payments in tax than we had earlier. And then the dividend. So, so we've had a long trend of more than ten years of paying a growing dividend. Now reading today's analyst reports in media, it seems like most people have misread it. Or maybe it's AI doing some of the parts, but it seems like the reports are stating that the dividend is $0.44. That is payable just as normal. If you read carefully what the board is proposing to the AGM, it's asking for authorization to decide separately on a dividend payment of up to $0.44 during this year. So, what the intention is or how investors should read it, is this: It's not certain that we will pay the dividend as normally after the AGM. But I'd say there's just as good a chance that the dividend is paid after summer. It's maybe smaller than$0.44 or there could be no dividend this year. So, that's just to clarify, and hopefully, I believe some of the articles have already been fixed during the day. Regarding shareholders, there have not been any major changes. Demant ownership slightly increased. Not much. The foreign ownership is up less than 1%. So the Finnish ownership is down for now. And then looking at the top ten list, that's mostly the same as SEB Funds and Evli Fund Management have fallen out. And we have Case Kapitalförvaltning and Handelsbanken that have come as owners on the top ten list during the quarter. And the guidance: we expect the exchange rate-adjusted net sales to grow 8 to 15% from the previous year, and profitability, excluding non-recurring items, is estimated to remain at a good level.

Jouni Toijala
18:57 - 19:00

Thank you, Robin. I think it's time for the questions.

Operator
19:07 - 19:31

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. The next question comes from Nico Ruokangas from SEB. Please go ahead.

Nico Ruokangas
19:33 - 20:08

Hello, this is Nico from SEB. Thank you for the presentation. I have three questions and I'll go one by one. And starting with your sales guidance. So could you discuss different building blocks behind the sales guidance and maybe their importance, although not exactly quantifying them? For example, the big deals in your pipeline, microperimeter growth, price increases, and underlying market growth, how important are they?

Jouni Toijala
20:09 - 20:52

If you look at the drivers. So what we see for this year. We see tonometry growing. We see fundus imaging growing. We see microperimetry growing. Those are the drivers. And of course, if we think about the USA. So the plan is to offset the tariffs now. And we were slightly delayed on that part. We have been discussing that for the USA in order to offset the tariffs for the US part of the business. It's roughly 4 to 5% that we have to increase the prices. But I think that's more or less in a nutshell. Anything to add on the driver's side. Robin.

Robin Pulkkinen
20:52 - 21:06

I think that to get to the upper end, we hopefully are successful in some of the larger deals we're working on. And the base assumption excluding those is hopefully somewhere in the middle. Those are the swing factors.

Nico Ruokangas
21:10 - 21:36

For example, the big deals in your pipeline, microperimeter growth, price increases and underlying market growth, how important are they? For example, the big deals in your pipeline, microperimeter growth, price increases, and underlying market growth, how important are they? For example, the big deals in your pipeline, microperimetry growth, price increases, and underlying market growth – how important are they? Then continuing on the price increases related to tariffs. What is the reason for lagging in price increases compared to your tariff costs? Now, as you already had pre-shipped inventory for six months ahead of the price increase. Prices are increasing.

Jouni Toijala
21:38 - 21:51

I think we were just perhaps too optimistic to get everything through the chain. So meaning? Meaning through the proposals and up to the customers. I think it was as simple as that.

Nico Ruokangas
21:55 - 22:06

All right. But you're now seeing that that is progressing. Thank you sir.

Jouni Toijala
22:07 - 22:12

Yes yes yes. Sorry. Yes yes. Sorry, we said yes. Yes. Sorry. Yes. So the answer is yes. Yeah.

Nico Ruokangas
22:13 - 22:41

Good. Then final one from me, you mentioned that your fixed costs should scale now in 2026, if excluding the FDA costs. But if you also include the FDA costs and gross margin headwinds from tariffs, should we expect an improving adjusted EBIT margin this year still?

Robin Pulkkinen
22:44 - 23:47

It depends a bit on where we hit the guidance. So it's maybe challenging on the lower end, but not if we're in the upper end. It is a very scalable model. Basically, we can grow 12%, or an additional 3% to 5%, amounting to over 5 million in additional sales. And it's still making a 70% margin on the additional sales. So I think it depends a bit where we hit on the guidance level. But I think the FDA is a bit tricky because we don't even know ourselves how much it's exactly going to be. And it's a one-time cost, but it affects the operating engine. So the clinical trial costs are not really generated by any of our people. It's kind of an outside service that we pay for. So, our internal opex should now be quite well under control, both in relation to overall growth and how top-line growth compares to cost growth.

Nico Ruokangas
23:50 - 23:52

All right. Good. Thanks. That's all from me.

Jouni Toijala
23:53 - 23:53

Thank you Niko.

Operator
24:00 - 24:07

The next question comes from Jack Reynolds Clark from RBC Capital Markets. Please go ahead.

Jack Reynolds Clark
24:10 - 24:38

Hi, Jouni. Hi, Robin. Thanks for taking the questions. Three for me also, please. So the first was on screening. Could you talk through how much growth in Q4 and 2025 was driven by screening, both in the hardware sales generated by the system and the reports that come out, and what your expectations are for 2026? And then I've got two more questions as well that I'll ask in a minute.

Jouni Toijala
24:39 - 25:58

Hi, Jack. So, on the screening side. So here I have to slightly disappoint you on the detailed numbers. So we don't disclose the kind of subgroup numbers, but I would perhaps frame it so that if we consider the EMEA region and the imaging sales, especially additional sales. So during 2025, we saw strong growth on the hardware side of the business. In the EMEA region, driven by the screening cases. So, regarding the amount of reports. We have doubled that one. We have tripled the number of live sites. And many of those also take the hardware. So on that front, it's scaling up quite nicely. But sorry to disappoint you slightly, Jack. So we are not able to give the sub-breakdowns per product group in terms of revenue. Yeah. Robin on this.

Robin Pulkkinen
25:58 - 26:32

Basically, the model is that we do recognize actually the whole hardware when we make a new deal for the screening center. So, upfront, the revenue is very hardware-weighted. But once the customer base and install base increases, we will start to see a bigger part of the revenue coming from the software and AI side as well. But now, you will have the hardware in day one and then the software for the following X years. In a way, it's very much front-loaded with hardware.

Jouni Toijala
26:33 - 27:13

And here, just to remind everybody about the business model. So we sell the hardware and then we sell the yearly recurring software license, which scales up based on the reports and the doctors' practices that are attached to the system. And then the third component is the AI reports, and the logic is a bit like the prepaid SIM card. So when you have run out of the minutes. So you have to top up to be able to speak. And here, if you want to run the reports and you're out of reports, you just have to buy a new set.

Jack Reynolds Clark
27:17 - 27:37

That's super helpful. So, if we are only talking about sales and marketing, there will be more direct sales efforts, less attention to distribution cooperation, and an increased focus on truly closing sales in the USA via our direct network. That's actually more than I was expecting. So thanks for the color there. The next question is on sales and marketing. So you talked about this being a strategic focus for you for 2026. Can you set out exactly what you're doing here? What the changes are and how that will feed through to revenue growth? So thank you.

Jouni Toijala
27:38 - 29:14

So I think it's good to go back to the end of the first half of 2025, when we were wondering what kind of approach we should have, especially in the USA. So, should we wait and sit still to see the impact the tariffs are going to have on the US business? But we took the other approach. So, we were more aggressive on the sales side. So we hired really good salespeople. So more really good salespeople for the USA. We increased the marketing expense regarding digital marketing in the USA and in other parts of the world to create more leads. And I think that explains and outlines also this year's strategic focus. So if only talking about the sales and marketing, so more direct engagement, less attention to the distribution cooperation, and more relentless focus on really closing sales in the USA via a direct network. And then, as you saw, we also recruited a top-notch global head for our marketing department. So, a strong background in marketing, product marketing, and general marketing across the globe. Couple of examples. Check on that front.

Jack Reynolds Clark
29:17 - 29:39

That's great. Thank you very much. And then my last question, Robin, you talked through one of the swing factors for guidance for top line guidance for next year. Obviously, contracts are one of them, but could you give any color on any other swing factors that we should be thinking about, any risk to the downside, or any other big things that might swing?

Robin Pulkkinen
29:40 - 30:24

Well, our internal plan is somewhere in the middle. Then, of course, we leave some more room for movement. Regarding any changes in the US economic environment, tariffs, or a sudden change in demand. Our visibility is quite limited. So our backlog, we've sold almost nothing for March even yet. So. So that's normal. That's normal. So in a way, we don't see that far into the future. So the baseline assumption is somewhere in the middle. And then the larger deals are kind of the swing factor there.

Jouni Toijala
30:25 - 30:48

What we see, of course, is the pipeline. And the pipeline is strong. So that's a good thing. And then also the year started so that we are well on track for the first couple of weeks.

Robin Pulkkinen
30:48 - 30:56

APAC, for example, has been a bit problematic now for two quarters. So hopefully we can turn that around during this year.

Jack Reynolds Clark
30:59 - 31:02

Great. Thanks very much. Appreciate the time.

Unknown 1
31:02 - 31:03

Thanks. Thanks.

Operator
31:08 - 31:14

The next question comes from Daniel Lepisto from Danske Bank. Please go ahead.

Daniel Lepisto
31:18 - 31:42

Hi, it's Daniel from Danske Bank. I have also a couple of questions, maybe still starting or continuing with the ILLUME and this 350 sites you have in operation. So can you give us any indication what kind of revenue potential there could be for one of these sites? Are we talking about thousands or, for example, hundreds of thousands? Any help here?

Jouni Toijala
31:44 - 32:26

And sorry, Daniel, no. And hi. So sorry. Not too much. So not too much. But it just shows the pace. The pace of getting the sites operational. And then of course, if you think of Germany. So then we have the unique connect feature, which then also combines the ophthalmologist to being part of the network. That's also picking up nicely. And it's a unique feature compared to the others. So we are bit by bit starting to build the ecosystem around the retina screening.

Robin Pulkkinen
32:26 - 32:36

There's a message that the audio stopped. Do you see? I just got a WhatsApp message saying that the audio cut off. Do you guys hear us on the line?

Jouni Toijala
32:37 - 32:38

Are you hearing us, Daniel?

Daniel Lepisto
32:40 - 32:41

Yes, I can hear you.

Unknown 1
32:41 - 32:42

Okay. Okay.

Robin Pulkkinen
32:42 - 32:43

Maybe it was some other problem.

Unknown 1
32:43 - 32:44

Okay, good. Okay.

Robin Pulkkinen
32:44 - 32:46

That's good. I got a WhatsApp that the audio cut off?

Unknown 1
32:46 - 32:47

Okay, okay.

Jouni Toijala
32:47 - 32:49

I think we are all set.

Unknown 1
32:49 - 32:50

Okay.

Daniel Lepisto
32:52 - 33:08

Okay. Okay. Maybe. Maybe if I. Then ask, is there any estimation how many such sites are there for you to address? If I put it this way? So you have 350. What's the universe that you are targeting? Any insight on this?

Jouni Toijala
33:08 - 33:18

No. Yes. But not willing to comment too much. So sorry for that one, Daniel.

Daniel Lepisto
33:19 - 33:42

Okay, maybe then on the capital expenditure. So if we look at 24, 25, there has been a small uplift. What about historical levels? It's like 4-5% of sales over the past few years. So is this the new normal level, or could there be a bit of a moderation looking forward?

Robin Pulkkinen
33:43 - 33:56

It depends a bit on the roadmap. So, once products start to come out, that always kind of changes the CapEx run rate. But it's probably something similar you could expect for this year.

Daniel Lepisto
33:58 - 34:18

Okay, maybe then on the capital expenditure. That's that's clear. Then my final question is, clinical trial costs. Can you give any sort of indication on the pacing of these costs? Will these run from Q1 onwards, or will this start from the summer, or any sense on the phasing, how this.

Robin Pulkkinen
34:18 - 34:18

Will it come, or?

Jouni Toijala
34:19 - 34:43

Yeah, maybe I take that one. So the biggest variable is how we are able to recruit the patients into the clinic. So the current assumption is that it's reasonably evenly split. But it depends on the pace of recruiting the patients. So that's the logic.

Robin Pulkkinen
34:44 - 34:48

And the next phase is still open.

Jouni Toijala
34:48 - 35:40

And here, one thing that's a good point, Robin. So, if we consider the structure of the clinical studies, we have faced a challenge and are delayed because we now have to run a so-called pre-study due to the high quality of doctors' images. And then we see and compare that one to the reference. Implementation or reference setup. And then most probably we have to fine-tune the algorithm so that it matches the worst quality imaging device, which is used as a reference. And then we have to start running the official clinical study. So those are the variables on this one.

Daniel Lepisto
35:44 - 35:55

Are these going to run from Q1 onwards, or will this start from the summer, or any sense on the phasing, how this? And can you clarify what's the latest timeline for securing FDA approval in the end. So, what's the timeline?

Jouni Toijala
35:55 - 36:03

So the latest on that one is towards the end of first half 2027. So that timeline hasn't changed.

Daniel Lepisto
36:05 - 36:07

That's clear. Will come or. That's all from me.

Jouni Toijala
36:07 - 36:08

Thank you Daniel.

Operator
36:14 - 36:21

The next question comes from Pia Rosqvist Hindsholm from NTB. Carnegie. Please go ahead.

Pia Rosqvist Hindsholm
36:25 - 36:50

Hi, gentlemen. It's Pia from DNB Carnegie. Thank you for taking my questions. I start by looking back at Q4 and your FX neutral growth of roughly 9%. Could you break that down? How much came from volume? How much from price increases? Given your comments on delayed price increases in the US.

Robin Pulkkinen
36:51 - 37:12

That's more volume-based. You had a record sale in the US in December? So, clearly better than ever before. So the volumes grew actually quite nicely. In Q4, we didn't actually have much price increases during that quarter.

Pia Rosqvist Hindsholm
37:17 - 37:35

It's Pia from DNB Carnegie. I start by looking back at Q4 and your FX neutral growth of roughly 9%. Then if I continue, regarding these larger than typical orders, do I understand correctly that these relate to imaging devices for screening purposes?

Jouni Toijala
37:36 - 37:45

Actually, no, generally in imaging and tonometers might be part of the picture as well. And specifically in the USA.

Pia Rosqvist Hindsholm
37:49 - 38:10

I start by looking back at Q4 and your FX neutral growth of roughly 9%. Claire. I start by looking back at Q4 and your FX neutral growth of roughly 9%. And, with regards to your comment on really strong sales in the US, particularly in December, are there any new client groups becoming more active or is this just a reflection of a broad demand?

Jouni Toijala
38:11 - 38:40

I think that the sales were good. Also on the broader terms, but we have been now getting to new tables, if I may use that phrase, where we haven't been before, thanks to the investments to the sales team during the end of first half. I think that's the logic.

Pia Rosqvist Hindsholm
38:43 - 38:59

It's Pia from Carnegie. Did you say? And, still on your gross margin, can you repeat, Robin, your comment on your indication of the gross margin for 2026, I missed that. Did you say?

Robin Pulkkinen
38:59 - 39:00

So we have.

Pia Rosqvist Hindsholm
39:00 - 39:02

We have remained below 70%.

Robin Pulkkinen
39:02 - 39:19

We have an internal magical 70 that we strive to reach with the gross margin. With the tariffs, it is of course a bit more challenging, but we definitely should be higher than what we now saw in Q4. So, closer to the 70 mark.

Pia Rosqvist Hindsholm
39:22 - 39:25

So closer, but still below.

Robin Pulkkinen
39:26 - 39:31

It could be above. Also depends a bit on the mix and everything.

Pia Rosqvist Hindsholm
39:34 - 39:53

All right. And then finally, can you remind us regarding center view and you allocated some of that purchase price, I presume, to be depreciated. Thank you. And then, two final short questions regarding the cash flow you referred to it as an exceptionally strong cash flow. Were there any exceptional items in that strong cash flow?

Robin Pulkkinen
39:53 - 40:09

No. No, it wasn't really. There was basically a small tax return that hit the Q4 numbers, but it's clearly less than a million. So other than that, it's business as usual.

Pia Rosqvist Hindsholm
40:12 - 40:34

All right, that's good. Thank you. And then finally, can you remind us regarding Centervue, and that you allocated some of that purchase price, I presume, to be depreciated? When are those depreciations coming to an end?

Robin Pulkkinen
40:35 - 40:54

If I remember right, the technology bucket was the biggest. And, I think it's ten years. So we still have some time to go. It could be seven or eight or ten, I remember. All right. Off the top of my head, I don't recall what the depreciation period is. But I think we still have some. I can check and come back to you separately if you want.

Pia Rosqvist Hindsholm
40:56 - 41:00

All right. That's great, and that's all for me. Thank you so much.

Robin Pulkkinen
41:00 - 41:01

The situation with the tariffs is of course a bit more challenging, but we definitely should be higher than what we now saw in Q4.

Jouni Toijala
41:01 - 41:02

Thank you PM.

Operator
41:07 - 41:13

The next question comes from Joni Sandoval from Nordea. Please go ahead.

Daniel Lepisto
41:15 - 41:29

Thanks, Joni, and Robin, for the presentation. Maybe starting with the new product pipeline, noticing that R&D costs were somewhat elevated in Q4. So could you give any more color on the new product pipeline for this year?

Jouni Toijala
41:31 - 42:17

So, perhaps a couple of viewpoints. And, Robin, please correct me if I'm wrong. So we have been doing a bit of an allocation. Right. So, certain FDA costs and clinical trials are now visible in the R&D bucket. So that might be the reason; I think otherwise. We have been running quite steadily at roughly 10% of revenue per year. Am I correct, Robin? Perhaps if you see elevated numbers. So the FDA costs are now coming as a part of the R&D cost bucket. I think that partly explains the lift up on the R&D costs.

Robin Pulkkinen
42:17 - 42:29

And then we have used outsourced R&D service providers. So those also go on a project basis, not necessarily evenly month after month. So there are some swings in those as well.

Daniel Lepisto
42:31 - 42:36

Thank you PM. And so we should expect something new also this year.

Jouni Toijala
42:37 - 42:56

Unfortunately, I cannot comment on that too much. But that I can comment on is that we have a good roadmap in mind for the products on the tonometry, fundus imaging, and perimetry side in the forthcoming years, with timing to be decided and communicated when they come out.

Daniel Lepisto
42:58 - 43:13

Okay. Thank you, Joni. Then my second question on the sales mix, Jouni mentioned that it depends a bit where you will end with the gross margin in 2026, but were there any specific aspects in the gross sales mix in Q4?

Robin Pulkkinen
43:14 - 43:47

No. It was actually all the main product groups were doing quite well. So nothing out of the ordinary. Normal over there. Also, it kind of depends on how the APAC currencies, for example, are already affecting APAC sales. So they're struggling with sales in euros. So, their hands are a bit tied regardless, at least when it comes to price increases there. And then in the US, of course, direct sales has a very good gross margin. So it depends on the geography as well. Slightly.

Daniel Lepisto
43:49 - 43:50

But the software part is still like the screening we discussed earlier, which is very hardware-heavy upfront. So nothing out of normal. That's all for me.

Jouni Toijala
43:51 - 43:52

It's normal over there. Ernie.

Operator
43:58 - 44:02

Please state your name and company. So nothing out of the ordinary.

Eric Olson
44:05 - 44:29

Hi, gents. It's Eric Olson from CPP capital. Three questions please. Regarding the gross margin from a slightly longer perspective, not focusing on 2026 but over the next two or three years, when you look at your product roadmap and where the business is heading, do you think gross margins will go up or down? And.

Robin Pulkkinen
44:29 - 44:30

Yeah.

Eric Olson
44:30 - 44:32

Maybe we take them one by one. It's easier.

Robin Pulkkinen
44:32 - 45:29

Maybe it's easier to remember. No, I think software and recurring revenue are starting to play a bigger part in the coming years. And that will have an increasing impact on the gross margin. So AI reports, for example, have more or less almost 100% gross margin in the software in general. So, definitely hope to see that actually increasing going forward. But the software part is still, like the screening we discussed earlier, very hardware-heavy up front. So once the installed base and the user base grow, that starts to have a bigger impact on the gross margin. And then I don't know what happens with the tariffs, but that's a separate problem that if it increases, it will probably have a lowering percent impact and vice versa.

Eric Olson
45:32 - 45:42

Got it. And on Microperimetry, what's your ambition there? Roughly how much sales can you generate or would you target this year?

Robin Pulkkinen
45:43 - 45:45

Microperimetry was it?

Eric Olson
45:46 - 45:46

Yeah, exactly.

Robin Pulkkinen
45:48 - 46:13

So historically, we've sold before the latest MAIA and the latest developments in geographic atrophy drug development. We used to sell 2 to 3 million a year. I think our message has been that we expect it to be clearly more than that. And then there's maybe do you want to only open the clinical potential on the MAIA side?

Jouni Toijala
46:14 - 47:05

Yes. So, we would, of course, be clearly disappointed if it's not way higher than previous years when we had the product. So I think that's crystal clear then. During 2026. So we are putting quite a lot of effort into pushing Maya out from research and also into clinical use to measure the efficacy of geographic atrophy-related drugs, and if we are able to be successful in that. So that's going to have a major impact also to the MAIA sales in years to come. But that's shortly the logic.

Eric Olson
47:08 - 47:40

That's helpful. And one last one, I think, on M&A, you talk about it. And then you mentioned that you're proposing to even postpone the dividend and even lower it. It's a bit unusual, I think. It seems to me it's a signal that you might do that in the event of M&A. What are you specifically looking at? What type of product categories or acquisitions would be most of interest to you?

Jouni Toijala
47:40 - 49:57

Perhaps to be clear on this one, so that we keep the two buckets separately, first commenting on the dividend. So, I think it was an ex-Volvo CEO that said in the 1980s that cash is king when there are turbulent times. Now, the logic why the board is proposing this setup is that we have a bit more freedom in these more unpredictable times, so that we maintain a bit more freedom to allocate capital into the best places. So, it's good to keep that in mind; then, the second topic is your comment related to M&A. And that has been on the table for quite a long time. So we would have been able to close already the deals on the M&A side, but we haven't closed them. And the reason simply is that they wouldn't have been good for our existing shareholders. So, the growth potential and profitability haven't matched the overall valuation. So we have been working quite heavily with Robin during the last quarters, during the last years, to fill the gap. The ophthalmic diagnostic device market where we operate is roughly €3.5 billion, and we currently cover only one third. So we have a 1 billion market coverage. And it would be great if, if in the coming years, coming quarters, we would be able to expand our product portfolio on the hardware side. And that would then enable us to go directly also in the big, big countries, and of course, bring scale to the top line, bring scale to the bottom line. I think that has been the logic on the inorganic growth side as a driver. But Robin, anything you would like to add on on this one?

Robin Pulkkinen
49:57 - 50:09

No, that's exactly right. We've been working on that quite a bit for a long time with Jouni and still remains on the agenda as we go into the new year.

Eric Olson
50:11 - 50:37

It's very much appreciated. Maybe a follow-up, but it's very much appreciated by shareholders that you're so disciplined on price. It seems to me at least the public market valuations have come down. You know, just look at the share price of Carl Zeiss Meditec or most names in ophthalmology. in the space. Do you also feel that in your M&A discussions that there are more realistic price expectations now, or has it not yet filtered down to slightly smaller companies?

Robin Pulkkinen
50:38 - 50:52

I think it's now becoming more reasonable. In the non-listed companies, for at least a couple of years, they were sticking to the high pricing from the COVID-19 pandemic.

Jouni Toijala
50:54 - 51:02

And quite often they were looking at our multiples and not growing as much and not making profit as much. But the multiples are more or less as expected.

Robin Pulkkinen
51:03 - 51:04

Expected to be the same?

Jouni Toijala
51:04 - 51:06

Expected to be the same?

Robin Pulkkinen
51:06 - 51:06

Yeah.

Eric Olson
51:08 - 51:09

But Robin, anything you would like to add on this one? Maybe a follow up, but it's very much appreciated by shareholders that you're so disciplined on price.

Jouni Toijala
51:10 - 51:11

Hey. Thank you Eric.

Operator
51:20 - 51:26

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Jouni Toijala
51:28 - 51:51

Thank you all. Thank you for your time. Thank you for the very good questions. And I think next time we are back in April with the Q1 earnings call. So thank you very much and have a nice spring when it comes. At least here in Finland, it doesn't seem to be arriving too soon. So thank you and have a good end of the week and good spring.

Robin Pulkkinen
51:51 - 51:52

Bye bye.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…